Source comparison
Thymosin Alpha-1 Chronic Infection Research: Mechanism Comparison
Chronic Hepatitis B Nucleos(t)ide analogue. Viral polymerase inhibition Restores CD8+ cytotoxic function; reduces PD-1 expression on T-cells HBeAg seroconversion: +13.3% vs monotherapy Chinese Academy of Medical Sciences (meta-analysis, 2018) Invasive Aspergil
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B
- Nucleos(t)ide analogue. Viral polymerase inhibition
- Restores CD8+ cytotoxic function; reduces PD-1 expression on T-cells
- HBeAg seroconversion: +13.3% vs monotherapy
- Chinese Academy of Medical Sciences (meta-analysis, 2018)
- Invasive Aspergillosis
- Azole antifungal. Ergosterol synthesis inhibition
- Accelerates neutrophil recovery; upregulates GM-CSF and macrophage ROS production
- 90-day mortality: 28% vs 47% standard therapy
- University of Perugia (RCT, 2016)
- Multidrug-Resistant TB
- Second-line antibiotics. Ribosomal or cell wall synthesis inhibition
- Enhances IL-12 and IFN-gamma; reduces regulatory T-cell suppression
- Sputum conversion: 76% vs 58% at 8 weeks
- Beijing Chest Hospital (Phase II trial, 2020)
- Chronic Hepatitis C (pre-DAA era)
- Pegylated interferon-alpha + ribavirin
- Potentiates endogenous IFN-alpha signaling; reduces Treg frequency
- SVR: 61% vs 47% in genotype 1 patients
- University of Rome (RCT, 2012)
- Bottom Line: Thymosin alpha-1 doesn't replace pathogen-targeted therapy. It corrects the immune dysfunction that allows pathogens to persist despite adequate antimicrobial drug levels. The clinical benefit is largest in patients with documented immune compromise (low CD4+ counts, neutropenia, elevated Treg frequencies).